Akebia Therapeutics, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Akebia increased authorized common stock from unspecified prior amount to 500M shares (total authorized stock 525M including 25M preferred) effective June 18, 2026. Separately, it extended its Cambridge, MA lab lease (1st floor, ~5,951 sq ft) through October 31, 2026 at $649,730/year annualized base rent plus $4,951/year tank fee. Two supply agreements with STA Pharmaceutical Hong Kong for vadadustat (drug substance and product) were amended April 28–30, 2026 to add federal contractor compliance language.
Why this rating
Share authorization increase is routine capital management; lease extension is minor and short-term (2 months); supply amendments are administrative compliance updates. None materially alter business trajectory or financials relative to $946M market cap.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.